Goldman Sachs Group Inc. Acquires 121,583 Shares of Emergent Biosolutions Inc. $EBS

Key Points

• Goldman Sachs Group Inc. increased its stake in Emergent Biosolutions by 12.5%, owning 1,090,655 shares valued at approximately $5.3 million after acquiring an additional 121,583 shares.
• Emergent Biosolutions has seen various institutional investors adjust their stakes, with some such as SBI Securities increasing holdings by 95.1% during the first quarter.
• The company's stock is currently valued at $7.98, down 2.0%, with analysts giving a consensus rating of "Buy" and an average target price of $13.50.

Goldman Sachs Group Inc. raised its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 12.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,090,655 shares of the biopharmaceutical company's stock after purchasing an additional 121,583 shares during the period. Goldman Sachs Group Inc. owned 2.01% of Emergent Biosolutions worth $5,301,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EBS. SBI Securities Co. Ltd. grew its holdings in Emergent Biosolutions by 95.1% during the first quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 6,313 shares during the last quarter. Corton Capital Inc. acquired a new position in Emergent Biosolutions during the first quarter valued at approximately $70,000. EP Wealth Advisors LLC grew its holdings in Emergent Biosolutions by 33.1% during the first quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 3,790 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Emergent Biosolutions by 40.4% during the first quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company's stock valued at $83,000 after purchasing an additional 4,894 shares during the last quarter. Finally, Alpine Global Management LLC acquired a new position in Emergent Biosolutions during the fourth quarter valued at approximately $112,000. Institutional investors and hedge funds own 78.40% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EBS. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, September 3rd. Wall Street Zen downgraded shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Emergent Biosolutions presently has a consensus rating of "Buy" and an average target price of $13.50.

Insider Transactions at Emergent Biosolutions

In related news, Director Kathryn C. Zoon sold 7,086 shares of Emergent Biosolutions stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $8.87, for a total value of $62,852.82. Following the completion of the transaction, the director directly owned 71,799 shares of the company's stock, valued at $636,857.13. The trade was a 8.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Donald W. Degolyer sold 7,844 shares of Emergent Biosolutions stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total value of $67,850.60. Following the completion of the transaction, the director directly owned 137,659 shares of the company's stock, valued at $1,190,750.35. This represents a 5.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.20% of the company's stock.

Emergent Biosolutions Stock Down 2.0%

Shares of NYSE EBS opened at $7.98 on Tuesday. The stock has a market cap of $425.73 million, a PE ratio of 3.26 and a beta of 2.03. The business has a fifty day moving average of $7.73 and a two-hundred day moving average of $6.44. Emergent Biosolutions Inc. has a 52-week low of $4.02 and a 52-week high of $12.73. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.42. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%.The business had revenue of $140.90 million during the quarter, compared to analysts' expectations of $148.55 million. As a group, equities research analysts expect that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.